Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TriSalus Life Sciences, Inc. - Common Stock (NQ:TLSI)

4.670 -0.070 (-1.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TriSalus Life Sciences, Inc. - Common Stock

< Previous 1 2 3 Next >
TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences to Participate in Upcoming September Investor Conferences
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Inc (NASDAQ:TLSI) Reports Strong Q2 2025 Revenue Growth and Narrowed Losses
TriSalus Life Sciences reports strong Q2 2025 revenue growth of 52% YoY to $11.2M, beating estimates. Losses narrow as commercialization of TriNav and PEDD platform gains momentum. 
Via Chartmill
TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance
From TriSalus Life Sciences
Via Business Wire
Examining the Future: TriSalus Life Sciences's Earnings Outlook
 
Via Benzinga
Earnings Scheduled For August 12, 2025
 
Via Benzinga
TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
Earnings Scheduled For May 15, 2025
 
Via Benzinga
TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences’ Q4 Loss Exceeds Projections, Revenue Tops Estimates – Retail Stays Pessimistic
The company reaffirmed its previous guidance for 2025 and said it expects sales growth of over 50% and its gross margin to exceed 87%, higher than the 86% reported for 2024. 
Via Stocktwits
TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update
From TriSalus Life Sciences
Via Business Wire
Earnings Scheduled For March 27, 2025
 
Via Benzinga
TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping
From TriSalus Life Sciences
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model”
From TriSalus Life Sciences
Via Business Wire
3 Stocks With Robust Growth Outlooks Insiders Are Buying
Insiders are buying these three stocks. The underlying companies have robust growth outlooks and are on track to deliver in 2025. 
Via MarketBeat
TriSalus Life Sciences Announces Key Appointments to Board of Directors
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call
From TriSalus Life Sciences
Via Business Wire
TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System
From TriSalus Life Sciences
Via Business Wire
TriSalus Announces Leadership Changes
From TriSalus Life Sciences
Via Business Wire
TriSalus Reports Q3 2024 Financial Results and Provides Business Update
From TriSalus Life Sciences
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.